Dupilumab provides favourable long-term safety and efficacy in children aged ≥ 6 to < 12 years with uncontrolled severe atopic dermatitis: results from an open-label phase IIa study and subsequent phase III open-label extension study

M. J. Cork, D. Thaçi, L. F. Eichenfield, P. D. Arkwright, X. Sun, Z. Chen, B. Akinlade, S. Boklage, I. Guillemin, M. P. Kosloski, M. A. Kamal, J. T. O’Malley, N. Patel, N. M.H. Graham, A. Bansal*

*Korrespondierende/r Autor/-in für diese Arbeit

Fingerprint

Untersuchen Sie die Forschungsthemen von „Dupilumab provides favourable long-term safety and efficacy in children aged ≥ 6 to < 12 years with uncontrolled severe atopic dermatitis: results from an open-label phase IIa study and subsequent phase III open-label extension study“. Zusammen bilden sie einen einzigartigen Fingerprint.

Medizin & Biologie